FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973135077> ?p ?o ?g. }

• W1973135077 endingPage "5583" @default.
• W1973135077 startingPage "5575" @default.
• W1973135077 abstract "Breast cancer recurrence is associated with significant morbidity, mortality, and cost. Patients with early stage HER2+ tumors are at increased risk of recurrence. The use of trastuzumab for these patients has been shown to reduce recurrences and improve overall survival.A Monte Carlo simulation was conducted based on Surveillance, Epidemiology, and End Results incidence rates for 2005, United States Census data for 2005, and the results of key trials of the adjuvant use of trastuzumab. Patients included in this analysis had incident, HER2+, stage I to III breast cancer. The number of recurrences that could be prevented with trastuzumab, the cardiac adverse events that might occur, and the associated cost savings were estimated.Approximately 31,200 women had HER2+ breast cancer in 2005, of whom 7298 would have had a recurrence over the subsequent 5 years despite standard of care adjuvant treatment. If trastuzumab were added to their regimen, 2791 women might have avoided recurrence, and 948 may have had an asymptomatic or symptomatic cardiac adverse event, for a ratio of expected recurrences to cardiac adverse events of 3.2 (95% confidence interval, 1.5-5.9). In economic terms, avoidance of future breast cancer recurrences was associated with lifetime reduction in future direct and indirect costs on the order of $240 million to $1.7 billion.On the basis of the simulation results, targeting HER2+ tumors with trastuzumab in the adjuvant setting should prevent a significant number of women from recurrence events, with important outcomes for patients, physicians, payers, and society." @default.
• W1973135077 created "2016-06-24" @default.
• W1973135077 creator A5018773741 @default.
• W1973135077 creator A5024474312 @default.
• W1973135077 creator A5032187510 @default.
• W1973135077 creator A5066583016 @default.
• W1973135077 creator A5072015843 @default.
• W1973135077 date "2010-08-23" @default.
• W1973135077 modified "2023-10-08" @default.
• W1973135077 title "Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States" @default.
• W1973135077 cites W1964641698 @default.
• W1973135077 cites W1967339606 @default.
• W1973135077 cites W1967599937 @default.
• W1973135077 cites W1969345980 @default.
• W1973135077 cites W1971931343 @default.
• W1973135077 cites W1974015647 @default.
• W1973135077 cites W1994788941 @default.
• W1973135077 cites W1999368908 @default.
• W1973135077 cites W2000798782 @default.
• W1973135077 cites W2022684250 @default.
• W1973135077 cites W2028021362 @default.
• W1973135077 cites W2037906500 @default.
• W1973135077 cites W2041414819 @default.
• W1973135077 cites W2059170159 @default.
• W1973135077 cites W2072533493 @default.
• W1973135077 cites W2073392370 @default.
• W1973135077 cites W2095156669 @default.
• W1973135077 cites W2101814490 @default.
• W1973135077 cites W2108103670 @default.
• W1973135077 cites W2116937653 @default.
• W1973135077 cites W2130900820 @default.
• W1973135077 cites W2133953673 @default.
• W1973135077 cites W2139107075 @default.
• W1973135077 cites W2140074016 @default.
• W1973135077 cites W2141393790 @default.
• W1973135077 cites W2144832904 @default.
• W1973135077 cites W2145257123 @default.
• W1973135077 cites W2146384083 @default.
• W1973135077 cites W2149198543 @default.
• W1973135077 cites W2149908785 @default.
• W1973135077 cites W2150662880 @default.
• W1973135077 cites W2151311059 @default.
• W1973135077 cites W2152647863 @default.
• W1973135077 cites W2158180864 @default.
• W1973135077 cites W2162511260 @default.
• W1973135077 cites W2165686484 @default.
• W1973135077 cites W2168267013 @default.
• W1973135077 cites W2233806202 @default.
• W1973135077 doi "https://doi.org/10.1002/cncr.25347" @default.
• W1973135077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20734398" @default.
• W1973135077 hasPublicationYear "2010" @default.
• W1973135077 type Work @default.
• W1973135077 sameAs 1973135077 @default.
• W1973135077 citedByCount "11" @default.
• W1973135077 countsByYear W19731350772012 @default.
• W1973135077 countsByYear W19731350772013 @default.
• W1973135077 countsByYear W19731350772014 @default.
• W1973135077 countsByYear W19731350772015 @default.
• W1973135077 countsByYear W19731350772020 @default.
• W1973135077 countsByYear W19731350772022 @default.
• W1973135077 crossrefType "journal-article" @default.
• W1973135077 hasAuthorship W1973135077A5018773741 @default.
• W1973135077 hasAuthorship W1973135077A5024474312 @default.
• W1973135077 hasAuthorship W1973135077A5032187510 @default.
• W1973135077 hasAuthorship W1973135077A5066583016 @default.
• W1973135077 hasAuthorship W1973135077A5072015843 @default.
• W1973135077 hasBestOaLocation W19731350771 @default.
• W1973135077 hasConcept C120665830 @default.
• W1973135077 hasConcept C121332964 @default.
• W1973135077 hasConcept C121608353 @default.
• W1973135077 hasConcept C126322002 @default.
• W1973135077 hasConcept C141071460 @default.
• W1973135077 hasConcept C143998085 @default.
• W1973135077 hasConcept C146357865 @default.
• W1973135077 hasConcept C151730666 @default.
• W1973135077 hasConcept C197934379 @default.
• W1973135077 hasConcept C2777863537 @default.
• W1973135077 hasConcept C2777910003 @default.
• W1973135077 hasConcept C2779786085 @default.
• W1973135077 hasConcept C2781413609 @default.
• W1973135077 hasConcept C44249647 @default.
• W1973135077 hasConcept C530470458 @default.
• W1973135077 hasConcept C61511704 @default.
• W1973135077 hasConcept C71924100 @default.
• W1973135077 hasConcept C86803240 @default.
• W1973135077 hasConceptScore W1973135077C120665830 @default.
• W1973135077 hasConceptScore W1973135077C121332964 @default.
• W1973135077 hasConceptScore W1973135077C121608353 @default.
• W1973135077 hasConceptScore W1973135077C126322002 @default.
• W1973135077 hasConceptScore W1973135077C141071460 @default.
• W1973135077 hasConceptScore W1973135077C143998085 @default.
• W1973135077 hasConceptScore W1973135077C146357865 @default.
• W1973135077 hasConceptScore W1973135077C151730666 @default.
• W1973135077 hasConceptScore W1973135077C197934379 @default.
• W1973135077 hasConceptScore W1973135077C2777863537 @default.
• W1973135077 hasConceptScore W1973135077C2777910003 @default.
• W1973135077 hasConceptScore W1973135077C2779786085 @default.
• W1973135077 hasConceptScore W1973135077C2781413609 @default.

• next